Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Ketamine for Sickle Cell Pain Crisis
NCT04005209Phase 4Withdrawn
- Sponsor
- Duke University
- Start
- Jan 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in sickle cell disease (SCD), sponsored by Duke University. Planned start Jan 2022; status: withdrawn.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04005209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005209.